communication to investors [company update]

8/21/2019 Communication to Investors [Company Update]

1/12

2014-15 Q4 results26-May-15

SUVEN Life Sciences

Communication to investors

Mar 2015


2/12

2014-15 Q4 results

Risk statement

Except for historical information, all of the statements, expectations

and assumptions, including expectations and assumptions,

contained in this presentation may be forward-looking statements

that involve a number of risks and uncertainties. Although Suven

attempts to be accurate in making these forward-looking statements,

it is possible that future circumstances might differ from the

assumptions on which such statements are based. Other important

factors which could cause these statements to differ materially

including outsourcing trends, economic conditions, dependence on

collaborative partnership programs, retention of key personnel,

technological advances and continued success in growth of salesthat may make our products/services offerings less competitive;

Suven may not undertake to update any forward-looking statements

that may be made from time to time.

26-May-15


3/12


FINANCIAL QUICK VIEW

Quarter 4 – Mar 2015

• Growth in revenue -13.28%

• Growth in PAT -47.70%• Growth in EBIDTA -45.46%

• Growth in Pre-R&D EBIDTA -31.13%

• Increase in R&D costs 25.18%• R&D cost on revenue 13.54%


4/12


FINANCIAL QUICK VIEW

Year ending – Mar 2015

• Growth in revenue 3.14%

• Growth in PAT -24.56%• Growth in EBIDTA -24.34%

• Growth in Pre-R&D EBIDTA -17.05%

• Increase in R&D costs 16.72%• R&D cost on revenue 10.57%


5/12

2014-15 Q4 results

MAJOR PROFITABILITY RATIOS

Q4 Mar 15 YE Mar 15

PAT to

Income

14.81% 20.54%

EBIDTA toIncome

23.17% 31.74%

Cash Flow to

Income

17.14% 22.76%

Pre-R&D

EBITDA toIncome

36.71% 42.31%

26-May-15


6/12


INCOME COMPARISON

200

1200

2200

3200

4200

5200

6200

Qtr Mar14 Qtr Mar15 YE Mar14 YE Mar15

1320.061144.73

5133.425294.36

R u p e e s M i l l i o n


7/12


PROFIT COMPARISON

0

200

400

600

800

1000

1200

1400

1600


324.06

169.49

1441.58

1087.5

R u p e e s M

i l l i o n


8/12


EBIDTA COMPARISON

0

500

1000

1500

2000

2500


486.4

265.28

2220.88

1680.4

R u p e e s M i l

l i o n


9/12


R & D – EXPENDITURE

50100

150

200

250

300

350

400

450

500


123.81

154.98

346.93559.63

R u p e e s M

i l l i o n


10/12


PRE-R&D EBIDTA

0

500

1000

1500

2000

2500

3000


610.20

420.26

2700.36

2240.02

R u p e e s M i l l i o n


11/12


PRE-R&D CASHFLOW

0

400

800

1200

1600

2000


470.61329.89

2009.43

1648.38

R u p e e s M

i l l i o n


12/12

2014-15 Q4 results

Updates for the quarter • Suven has 743 product patents for 26 inventions and 37 process

patents for 7 inventions

• SUVN-502 completed phase 1b clinical trial in USA is in preparation

for Phase 2a (POC) study on patients in USA

• SUVN G-3031 undergoing phase 1 clinical trial in USA

• SUVN D-4010 undergoing IND enabling toxicological studies in USAin preparation for Phase 1 clinical trial.

• Number of active CRAMS projects - 110

• The Board has proposed a Dividend of Re.0.60 per share (60% of

face value Rs. 1.00 each) for the financial year 2014-15, subject to

approval of the shareholders in the ensuing Annual GeneralMeeting.

26-May-15

communication to investors [company update]

Documents